JENNISON ASSOCIATES LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 150 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.3%.

Quarter-by-quarter ownership
JENNISON ASSOCIATES LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$740,013
-98.4%
26,890
-98.0%
0.00%
-97.3%
Q2 2023$45,096,193
-20.8%
1,329,095
-16.0%
0.04%
-28.8%
Q1 2023$56,923,600
-17.9%
1,582,090
+1.7%
0.05%
-25.7%
Q4 2022$69,320,523
+93.6%
1,555,318
+22.1%
0.07%
+94.4%
Q3 2022$35,813,0001,274,0210.04%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q2 2023
NameSharesValueWeighting ↓
Kynam Capital Management, LP 2,600,000$88,218,00012.13%
Octagon Capital Advisors LP 759,898$25,783,3393.59%
TSP Capital Management Group, LLC 251,895$8,546,8003.08%
ACUTA CAPITAL PARTNERS, LLC 122,343$4,151,0982.81%
5AM Venture Management, LLC 310,270$10,527,4612.62%
COMMODORE CAPITAL LP 631,665$21,432,3932.41%
RTW INVESTMENTS, LP 3,463,201$117,506,4102.24%
Eversept Partners, LP 785,740$26,660,1582.23%
Redmile Group, LLC 1,696,004$57,545,4162.21%
Affinity Asset Advisors, LLC 87,031$2,952,9621.03%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders